Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma

Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma

(2013) Akiyo Tanabe et al.   Hormones & Cancer

Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas

(2012) Do-Youn Oh et al.   CANCER

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

(2012) N. Burnichon et al.   CLINICAL CANCER RESEARCH

Radionuclide Therapy in Neuroendocrine Tumours: A Systematic Review

(2012) K.Y. Gulenchyn et al.   CLINICAL ONCOLOGY

Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma

(2012) L. Amar et al.   HORMONE AND METABOLIC RESEARCH

Prevalence and Spectrum of SDHx Mutations in Pheochromocytoma and Paraganglioma in Patients from Belgium: An Update

(2012) A. Persu et al.   HORMONE AND METABOLIC RESEARCH

High Incidence of Cardiovascular Complications in Pheochromocytoma

(2012) T. Zelinka et al.   HORMONE AND METABOLIC RESEARCH

Metastatic Pheochromocytoma and Paraganglioma: Focus on Therapeutics

(2012) P.-F. Plouin et al.   HORMONE AND METABOLIC RESEARCH

Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma

(2012) Nelly Burnichon et al.   HUMAN MOLECULAR GENETICS

Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused bySDHBGene Mutations

(2012) Céline Loriot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas

(2012) Montserrat Ayala-Ramirez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Renal Tumors Associated With Germline SDHB Mutation Show Distinctive Morphology

(2011) Anthony J. Gill et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

(2011) Ana M. Molina et al.   CANCER

Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas

(2011) Montserrat Ayala-Ramirez et al.   CANCER

Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma

(2011) Judith Favier et al.   ENDOCRINE PATHOLOGY

Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma

(2011) Nelly Burnichon et al.   HUMAN MOLECULAR GENETICS

Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients

(2011) Feng Feng et al.   JOURNAL OF UROLOGY

Minimally Invasive Treatment of Metastatic Pheochromocytoma and Paraganglioma: Efficacy and Safety of Radiofrequency Ablation and Cryoablation Therapy

(2011) Jeremy F. McBride et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

(2011) Iñaki Comino-Méndez et al.   NATURE GENETICS

Malignant Pheochromocytoma Metastasis to the Breast Shown on I-123 MIBG Scan

(2010) Mihir Patel et al.   CLINICAL NUCLEAR MEDICINE

Are we overestimating the penetrance of mutations in SDHB?

(2010) Francesca Schiavi et al.   HUMAN MUTATION

A Current Review of the Etiology, Diagnosis, and Treatment of Pediatric Pheochromocytoma and Paraganglioma

(2010) S. G. Waguespack et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators

(2010) Montserrat Ayala-Ramirez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas

(2010) Elena López-Jiménez et al.   MOLECULAR ENDOCRINOLOGY

Paraganglioma syndrome type 1 in a patient with Carney–Stratakis syndrome

(2010) Montserrat Ayala-Ramirez et al.   Nature Reviews Endocrinology

Update on systemic therapies of metastatic renal cell carcinoma

(2010) E. Herrmann et al.   WORLD JOURNAL OF UROLOGY

Malignant pheochromocytoma

(2009) J. Mundschenk et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies

(2009) L. Santarpia et al.   HORMONE AND METABOLIC RESEARCH

Treatment of Malignant Pheochromocytoma

(2009) R. Adjallé et al.   HORMONE AND METABOLIC RESEARCH

Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)

(2009) M. R. Druce et al.   HORMONE AND METABOLIC RESEARCH

Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma

(2009) K.-S. Park et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Comparison of18F-Fluoro-L-DOPA,18F-Fluoro-Deoxyglucose, and18F-Fluorodopamine PET and123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma

(2009) Henri J. L. M. Timmers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas

(2009) Nelly Burnichon et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma

(2009) Sara Gonias et al.   JOURNAL OF CLINICAL ONCOLOGY

An Unusual Case of Severe Constipation Due to Metastatic Pheochromocytoma

(2009) Louise D. Mason et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis

(2009) Francien H van Nederveen et al.   LANCET ONCOLOGY

The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas

(2009) Judith Favier et al.   PLoS One

Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine

(2008) Hui Huang et al.   CANCER

Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma

(2008) H J L M Timmers et al.   ENDOCRINE-RELATED CANCER

Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations

(2008) T. Zelinka et al.   ENDOCRINE-RELATED CANCER

Current Progress and Future Challenges in the Biochemical Diagnosis and Treatment of Pheochromocytomas and Paragangliomas

(2008) G. Eisenhofer et al.   HORMONE AND METABOLIC RESEARCH

Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma

(2008) Anthony M. Joshua et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors

(2008) Camilo Jimenez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM